A share price of Summit Therapeutics Inc [SMMT] is currently trading at $19.68, up 4.51%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SMMT shares have gain 12.33% over the last week, with a monthly amount glided 15.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on December 17, 2025, when Barclays upgraded its rating to a Equal Weight but kept the price target unchanged to $18 for it. On September 17, 2025, Barclays initiated with a Underweight rating and assigned a price target of $13 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $40 on September 04, 2025. Piper Sandler initiated its recommendation with a Neutral and recommended $21 as its price target on August 19, 2025. UBS started tracking with a Buy rating for this stock on July 01, 2025, and assigned it a price target of $30. In a note dated June 11, 2025, Leerink Partners initiated an Underperform rating and provided a target price of $12 on this stock.
Summit Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $15.55 and $36.91. Currently, Wall Street analysts expect the stock to reach $24.67 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $19.68 at the most recent close of the market. An investor can expect a potential return of 25.36% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.52, Equity is -3.11 and Total Capital is -4.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Summit Therapeutics Inc [NASDAQ:SMMT] is 3.80. Also, the Quick Ratio is 3.80, while the Cash Ratio stands at 3.68.
Transactions by insiders
Recent insider trading involved Xia Yu, Director, that happened on Oct 21 ’25 when 0.53 million shares were purchased. Co-Chief Executive Officer, DUGGAN ROBERT W completed a deal on Oct 21 ’25 to buy 26680.0 shares. Meanwhile, Co-Chief Executive Officer Zanganeh Mahkam bought 26680.0 shares on Oct 21 ’25.
